Search results for "Retrospective"

showing 10 items of 3553 documents

Mortality risk among 5‐year survivors of childhood cancer in Germany—Results from the CVSS study (Cardiac and Vascular late Sequelae in long‐term Sur…

2021

The growing population of long-term childhood cancer survivors is at increased risk for severe, therapy-related late effects and premature mortality. The cardiac and vascular late sequelae in long-term survivors of childhood cancer (CVSS) study is a cohort of patients from Germany diagnosed with a neoplasia prior to 15 years of age in the time period 1980 to 1990. Late mortality was evaluated in a total of 4505 individuals who survived 5 years or more after the initial diagnosis (5-year survivors). Survivors with a second primary tumor were excluded. Standardized mortality ratios (SMRs) were calculated. By December 2014, 400 patients had died. Available cause of death information from 188 i…

AdultMaleCancer ResearchPediatricsmedicine.medical_specialtyTime FactorsAdolescentPopulationChildhood cancerYoung AdultCancer SurvivorsCause of DeathGermanyNeoplasmsmedicineHumansMortalityChildeducationRetrospective StudiesCause of deatheducation.field_of_studybusiness.industryInfant NewbornInfantCancerPrognosismedicine.diseaseConfidence intervalSurvival RateOncologyCardiovascular DiseasesChild PreschoolCVSSCohortDisease ProgressionFemalebusinessFollow-Up StudiesCohort studyInternational Journal of Cancer
researchProduct

Cardiovascular Risk in Polycythemia Vera: Thrombotic Risk and Survival: Can Cytoreductive Therapy Be Useful in Patients with Low-Risk Polycythemia Ve…

2019

<b><i>Background/Aims:</i></b> Cardiovascular risk factors are not considered in the current scores for evaluation of the thrombotic risk in myeloproliferative neoplasms, and in polycythemia vera (PV) in particular. Cytoreduction is currently not indicated in low-risk patients with PV, despite the absence or presence of cardiovascular risk factors. Our purpose is to highlight how cardiovascular risk factors in patients with PV increase the thrombotic risk both in low- and high-risk patients. <b><i>Methods:</i></b> We collected and analyzed data from 165 consecutive patients with a diagnosis of PV followed at our institution and compared the fr…

AdultMaleCancer Researchmedicine.medical_specialtyAdolescentPopulationCardiovascular risk factorsKaplan-Meier EstimateSettore MED/15 - Malattie Del SangueCytoreductionYoung AdultPolycythemia veraSurvival dataInternal medicinemedicineHumansIn patienteducationAgedRetrospective StudiesAged 80 and overThrombotic riskeducation.field_of_studybusiness.industryThrombosisCytoreduction Surgical ProceduresHematologyMiddle AgedCardiovascular riskmedicine.diseaseThrombosisPolycythemia veraOncologyCardiovascular DiseasesHeart Disease Risk FactorsRisk stratificationFemalebusinessOncology Research and Treatment
researchProduct

Impact of relative dose intensity of oxaliplatin in adjuvant therapy among stage III colon cancer patients on early recurrence: a retrospective cohor…

2020

Abstract Background Oxaliplatin-based therapy with FOLFOX-4 or CAPOX administered over 6 months remains the standard adjuvant treatment for stage III colon cancer (CC) patients. However, many patients experience dose reduction or early termination of chemotherapy due to oxaliplatin toxicity, which may increase the risk of early recurrence. The objective of this study was to analyze the relationship between the relative dose intensity of oxaliplatin (RDI-O) and early recurrence among stage III CC patients. Methods The study included 365 patients treated at five oncology centers in Poland between 2000 and 2014. Survival analysis was performed using the Kaplan-Meier method. Univariate analysis…

AdultMaleCancer Researchmedicine.medical_specialtyColorectal cancerGastroenterology03 medical and health sciences0302 clinical medicineInternal medicineGeneticsAdjuvant therapyMedicineHumans030212 general & internal medicineRelative dose intensityRC254-282Survival analysisAgedNeoplasm StagingRetrospective StudiesAged 80 and overUnivariate analysisbusiness.industryCumulative doseProportional hazards modelNeoplasms. Tumors. Oncology. Including cancer and carcinogensRetrospective cohort studyMiddle Agedmedicine.diseaseCumulative doseOxaliplatinColon cancerAdjuvant chemotherapyOxaliplatinOncologyChemotherapy Adjuvant030220 oncology & carcinogenesisColonic NeoplasmsFemaleNeoplasm Recurrence Localbusinessmedicine.drugResearch Article
researchProduct

Implication of the Examining Pathologist to Meet the Oncologic Standard of Lymph Node Count after Laparoscopic Lymphadenectomy

2010

<i>Objective:</i> The lymph node number as benchmark in oncologic operations depends on the patient’s anatomy, surgeon’s skill and pathologist’s accuracy. The influence of the pathologist is barely evaluated. <i>Methods:</i> A retrospective analysis of lymph node numbers after 700 laparoscopic lymphadenectomies in correlation to the examining pathologists was done. Three surgeons from the same department performed all operations at 2 campi, where 2 separate pathology institutions exist. Lymph node specimens were assigned randomly to any of the 62 involved pathologists. <i>Results:</i> The mean number of lymph nodes was equal for all surgeons. Lymph node s…

AdultMaleCancer Researchmedicine.medical_specialtyPathologyAdolescentPelviPathology Surgicalmedicine.medical_treatmentGynecologic oncologyMedical OncologyPelvisYoung AdultRetrospective StudieGynecologic oncology; Laparoscopic lymphadenectomy; Lymph node numberNeoplasmsHumansMedicineLaparoscopyLaparoscopic lymphadenectomyLymph nodeAgedNeoplasm StagingRetrospective StudiesAged 80 and overLaparoscopic lymphadenectomymedicine.diagnostic_testbusiness.industryGeneral surgeryLymph NodeGeneral MedicineMiddle AgedSettore MED/40 - Ginecologia E Ostetriciadigestive system diseasesEndoscopyGynecologic oncologysurgical procedures operativemedicine.anatomical_structureOncologyLymph node numberPractice Guidelines as TopicNeoplasmLymph Node ExcisionFemaleLaparoscopyLymphadenectomyLymph NodesbusinessHumanOncology
researchProduct

Incidence and long-term prognosis of papillary compared to clear cell renal cell carcinoma--a multicentre study.

2012

Abstract Aim of the study Papillary renal cell carcinoma (pRCC) is the second most common subtype of RCC after the conventional clear cell type (cRCC). However, its characteristics and prognosis have been less intensively investigated. The aim of our study was to examine the tumour characteristics and long-term prognosis of pRCC compared to clear cell RCC (cRCC). Methods In total, 4941 evaluable patients were subjected to either radical nephrectomy or nephron-sparing surgery for pRCC or cRCC at five centres in Germany (University Hospitals of Hannover, Homburg/Saar, Mainz, Ulm and Marburg) between 1990 and 2010. Results pRCC ( n  = 565) and cRCC ( n  = 4376) patients were comparable with re…

AdultMaleCancer Researchmedicine.medical_specialtyPathologymedicine.medical_treatmentGastroenterologyYoung AdultInternal medicineGermanyCarcinomaMedicineHumansSurvival rateCarcinoma Renal CellAgedRetrospective StudiesAged 80 and overPapillary renal cell carcinomasbusiness.industryIncidenceMiddle Agedmedicine.diseasePrognosisNephrectomyKidney NeoplasmsSurvival RateClear cell renal cell carcinomaOncologyClear cell carcinomaFemalebusinessKidney cancerClear cellEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Correlation between GP-170 expression, prognosis, and chemoresistance of superficial bladder carcinoma.

2003

To study GP-170 in superficial bladder cancer at initial diagnosis and at recurrence and to evaluate if intravesical chemoprophylaxis modifies the expression of GP-170 in tumor recurrences. GP-170 was retrospectively assessed in 160 patients affected by primary superficial transitional cell carcinoma of the bladder and followed for up to 10 years. Eighty-four patients (52.5%) recurred after transurethral resection (TUR). Adjuvant intravesical chemotherapy after TUR was adopted in 52 patients. The correlations between GP-170 and G-grade, T-category, risk of recurrence and of progression, and adoption of adjuvant intravesical chemotherapy were investigated. The correlations between variations…

AdultMaleCancer Researchmedicine.medical_specialtyPathologymedicine.medical_treatmentUrologySettore MED/24 - UrologiaSuperficial bladder carcinoma GP-170 MDR-1 Prognosis Intravesical chemotherapyInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineCarcinomaHumansATP Binding Cassette Transporter Subfamily B Member 1Stage (cooking)AgedRetrospective StudiesChemotherapyHematologyUrinary bladderbusiness.industryGeneral MedicineMiddle Agedmedicine.diseasePrognosisDrug Resistance MultipleGene Expression Regulation NeoplasticTransitional cell carcinomamedicine.anatomical_structureOncologyUrinary Bladder NeoplasmsChemotherapy AdjuvantDrug Resistance NeoplasmChemoprophylaxisFemaleSuperficial Bladder CarcinomaGenes MDRNeoplasm Recurrence LocalbusinessFollow-Up StudiesJournal of cancer research and clinical oncology
researchProduct

Primary cutaneous melanoma in hidden sites is associated with thicker tumours — a study of 829 patients

2001

The aim of this study was to determine if primary cutaneous melanomas in hidden anatomical sites were associated with thicker tumours. Retrospective medical data of 829 patients with melanomas diagnosed at our centre between January 1976 and July 1998 were recorded from our database. Three groups were defined according to the anatomical site of the primary melanoma: (1) visible areas (group 1: 493 patients); (2) visible areas only to the patients or to their partners in privacy (group 2: 281 patients); and (3) hidden areas (group 3: 55 patients). Univariate analysis indicated that patients with melanoma in hidden regions presented significantly thicker tumours (median for group 3: 2.25 vers…

AdultMaleCancer Researchmedicine.medical_specialtySkin NeoplasmsMultivariate analysisAdolescentDiseaseBreslow ThicknessSex FactorsInternal medicinemedicineHumansMelanomaAgedNeoplasm StagingRetrospective StudiesAged 80 and overAnalysis of VarianceUnivariate analysisbusiness.industryMelanomaAge FactorsRetrospective cohort studyMiddle Agedmedicine.diseaseSurgeryAnatomical sitesOncologyCutaneous melanomaFemalebusinessEuropean Journal of Cancer
researchProduct

Surgery-triggered and non surgery-triggered Bisphosphonate-related Osteonecrosis of the Jaws (BRONJ): A retrospective analysis of 567 cases in an Ita…

2011

Invasive local procedures are often reported in clinical history of patients suffering from Bisphosphonates-Related Osteonecrosis of the Jaws (BRONJ) but over 40% of spontaneous forms have been also described in literature. We compared age, gender, underlying bone disorders, bisphosphonate therapy, clinical features and surgical outcome of 205 cases (36.2%) of BRONJ non surgery-triggered (group 1) with 362 (63.8%) cases of surgery-triggered forms (group 2). Differences between group 1 and 2 were analysed using Mann-Whitney U and χ2 tests. Statistical analysis was performed using STATA 8. Zoledronate was the most used type of bisphosphonate (63.4% versus 69.0%) and the mandible was the most …

AdultMaleCancer Researchmedicine.medical_specialtyTooth extractionmedicine.medical_treatmentZoledronic AcidSettore MED/28 - Malattie OdontostomatologicheRisk FactorsClinical historySpontaneous formmedicineRetrospective analysisHumansStatistical analysisStage (cooking)AgedRetrospective StudiesAged 80 and overSurgical outcomeBone Density Conservation AgentsDiphosphonatesBRONJOrthognathic Surgical Proceduresbusiness.industryImidazolesOsteonecrosisBisphosphonates-related Osteonecrosis of the JawMiddle AgedBisphosphonateSurgeryZoledronic acidItalyOncologyMulticenter studyFemaleBisphosphonate therapyOral SurgerybusinessJaw Diseasesmedicine.drugOral Oncology
researchProduct

Hematopoietic stem-cell transplantation for advanced systemic mastocytosis

2014

Purpose Advanced systemic mastocytosis (SM), a fatal hematopoietic malignancy characterized by drug resistance, has no standard therapy. The effectiveness of allogeneic hematopoietic stem-cell transplantation (alloHCT) in SM remains unknown. Patients and Methods In a global effort to define the value of HCT in SM, 57 patients with the following subtypes of SM were evaluated: SM associated with clonal hematologic non–mast cell disorders (SM-AHNMD; n = 38), mast cell leukemia (MCL; n = 12), and aggressive SM (ASM; n = 7). Median age of patients was 46 years (range, 11 to 67 years). Donors were HLA-identical (n = 34), unrelated (n = 17), umbilical cord blood (n = 2), HLA-haploidentical (n = 1)…

AdultMaleCancer Researchmedicine.medical_specialtyTransplantation ConditioningAdolescentmedicine.medical_treatmentMedizinDrug resistanceHematopoietic stem cell transplantationMastocytosis SystemicInternal medicinemedicineHumansTransplantation HomologousSystemic mastocytosisChildSurvival rateAgedRetrospective StudiesmastocytosisHematologybusiness.industryRemission InductionHematopoietic Stem Cell TransplantationORIGINAL REPORTSMiddle Agedmedicine.diseaseMast cell leukemia3. Good healthSurvival RateTransplantationSettore MED/15 - MALATTIE DEL SANGUEHaematopoiesisTreatment OutcomeOncologyImmunologyCancer researchFemalebusinesstransplantation
researchProduct

Protective effect of amifostine on dental health after radiotherapy of the head and neck.

2000

Abstract Purpose: The cytoprotective agent amifostine has been shown to reduce the radiation-induced acute and chronic xerostomia in head and neck cancer patients. The purpose of this study was to evaluate whether or not amifostine also reduces the incidence of dental caries associated with the radiation-induced xerostomia. Methods and Materials: The dental status before and 1 year after radiotherapy was retrospectively compared in 35 unselected patients treated as part of the prospective randomized and multicenter open-label Phase III study (WR-38) at the University Hospitals of Heidelberg, Freiburg, and Erlangen. The WR-38 study compared radiotherapy in head and neck cancer with and witho…

AdultMaleCancer Researchmedicine.medical_specialtymedicine.medical_treatmentRadiation-Protective AgentsDental CariesXerostomiasymbols.namesakeAmifostinestomatognathic systemOral and maxillofacial pathologymedicineClinical endpointHumansRadiology Nuclear Medicine and imagingProspective StudiesRadiation InjuriesFisher's exact testAgedRetrospective StudiesRadiationbusiness.industryHead and neck cancerCase-control studyAmifostineMiddle Agedmedicine.diseaseSurgeryRadiation therapystomatognathic diseasesOncologyHead and Neck NeoplasmsConcomitantsymbolsFemalebusinessmedicine.drugInternational journal of radiation oncology, biology, physics
researchProduct